Hirofumi Kosuge

ORCID: 0009-0007-7411-7948
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Muscle Physiology and Disorders
  • Glycosylation and Glycoproteins Research
  • Caveolin-1 and cellular processes
  • Monoclonal and Polyclonal Antibodies Research
  • Cardiomyopathy and Myosin Studies
  • Peptidase Inhibition and Analysis
  • Histone Deacetylase Inhibitors Research
  • RNA Research and Splicing
  • Advanced biosensing and bioanalysis techniques
  • Protein purification and stability
  • Cancer-related Molecular Pathways
  • Genetics and Neurodevelopmental Disorders
  • ATP Synthase and ATPases Research
  • Ocular Oncology and Treatments
  • Cardiovascular and Diving-Related Complications
  • Cancer, Hypoxia, and Metabolism
  • Barrier Structure and Function Studies
  • Surface Chemistry and Catalysis
  • Metabolism, Diabetes, and Cancer
  • Chemical Synthesis and Analysis
  • Cardiac Structural Anomalies and Repair
  • CRISPR and Genetic Engineering
  • Lipid metabolism and disorders
  • Cholesterol and Lipid Metabolism
  • Asymmetric Synthesis and Catalysis

The University of Tokyo
2020-2023

Kumamoto University
2009-2013

Tokyo University of Agriculture and Technology
2008

Retinoblastoma (RB) is the most common intraocular pediatric cancer. Nearly all cases of RB are associated with mutations compromising function RB1 tumor suppressor gene. We previously demonstrated that PRELP widely downregulated in various cancers and our vivo vitro analysis revealed as a novel regulator EMT. In addition, located at chromosome 1q31.1, around region hypothesized to be initiation malignancy RB. Therefore, this study, we investigated role through next-generation sequencing....

10.3390/cancers14194926 article EN Cancers 2022-10-08

Proline and arginine-rich end leucine-rich repeat protein (PRELP) is a member of the small proteoglycans (SLRPs) family. Levels PRELP mRNA are downregulated in many types cancer, has been reported to have suppressive effects on tumor cell growth, although molecular mechanism yet be fully elucidated. Given that other SLRPs regulate signaling pathways through interactions with various membrane proteins, we reasoned likely interacts proteins maintain cellular homeostasis. To identify interact...

10.1016/j.jbc.2021.100278 article EN cc-by Journal of Biological Chemistry 2021-01-01

Proline/arginine-rich end leucine-rich repeat protein (PRELP) is a member of the small proteoglycan family extracellular matrix proteins, which markedly suppressed in majority early-stage epithelial cancers and plays role regulating epithelial-mesenchymal transition by altering cell-cell adhesion. Although PRELP an important factor development progression bladder cancer, mechanism gene repression remains unclear.Here, we show that mRNA expression cancer cells alleviated HDAC inhibitors...

10.1186/s13148-022-01370-z article EN cc-by Clinical Epigenetics 2022-11-12

Introduction: Proline/arginine-rich end leucine-rich repeat protein (PRELP), is a small secreted proteoglycan expressed by pericytes and vascular smooth muscle cells surrounding the brain vasculature of adult mouse. Methods: We utilised Prelp knockout (Prelp-/-) mouse model to interrogate integrity in alongside performing vitro assays characterise PRELP application endothelial lines. Our findings were supplemented with RNA expression profiling elucidate mechanism how maintains...

10.3389/fcell.2023.1147625 article EN cc-by Frontiers in Cell and Developmental Biology 2023-10-23

The cell-surface receptor FcγRIIIa is crucial to the efficacy of therapeutic antibodies as well immune response. interaction Fc region IgG molecules with has been characterized, but until recently, it was thought that Fab regions were not involved in interaction. To evaluate influence a biophysical context, we carried out surface plasmon resonance analyses using recombinant ligands. A van't Hoff analysis revealed compared papain-digested fragment FcγRIIIa, commercially available, full-length...

10.1021/acs.biochem.1c00832 article EN cc-by-nc-nd Biochemistry 2022-05-23

Quality control of monoclonal antibodies is challenging due in part to the diversity post-translational modifications present. The regulation N-glycans IgG-Fc domain one key factors maintain safety and efficacy antibody drugs. FcγRIIIa affinity column an attractive tool for precise analysis domain. We used mutant FcγRIIIa, which produced Escherichia coli therefore not glycosylated, as reagent analyze expressed Expi293 ExpiCHO cells. these cells showed very different chromatograms, because...

10.1002/btpr.3016 article EN cc-by-nc-nd Biotechnology Progress 2020-05-11

Duchenne muscular dystrophy (DMD) and Becker (BMD) are caused by abnormalities in the DMD gene. The majority of patients have out-of-frame deletion(s), which disrupt reading frame; while some cases duplication or nonsense mutation(s). Most with BMD in-frame preserve frame. phenotype is generally milder than that DMD. Antisense morpholino-mediated exon skipping, changes deletions to deletions, a promising therapeutic approach for It necessary, however, confirm exon-skipping event cells before...

10.1111/j.1442-200x.2011.03330.x article EN Pediatrics International 2011-02-23

Abstract Vigorous mechanical mixing of the water/hexane biphasic Pd-catalyzed allylation benzenethiol gave sterically congested allyl sulfides, due to high reactivity enforced orientation η1-allylpalladium intermediate at solvent interface.

10.1246/cl.2008.640 article EN Chemistry Letters 2008-05-17

Congenital fiber type disproportion (CFTD) is a form of congenital myopathy, which defined by 1 myofibers that are 12% smaller than 2 myofibers, as well general predominance myofibers. Conversely, myasthenia gravis (MG) an acquired immune-mediated disease, in the acetylcholine receptor (AChR) neuromuscular junction blocked antibodies. Thus, anti-AChR antibody nearly specific to MG. Herein, we report on case CFTD with increased levels. A 23-month-old boy exhibited muscle hypotonia and...

10.1155/2013/607678 article EN cc-by Case Reports in Pediatrics 2013-01-01
Coming Soon ...